Interferon Beta-1B

Evidence Level: L5

Predicted Indications: 2

Interferon Beta-1B

Pharmacist Assessment Report

Interferon Beta-1b: From Relapsing-Remitting Multiple Sclerosis to Hairy Cell Leukemia

One-Sentence Summary

Interferon beta-1b was originally developed to treat relapsing-remitting multiple sclerosis (RRMS). The TxGNN model predicts it may be effective for hairy cell leukemia, but the compiled data contain 0 clinical trials and 0 publications for this indication, so the prediction rests on the model score and class-level reasoning alone.

Quick Overview

Item	Content
Original Indication	Relapsing-remitting multiple sclerosis
Predicted New Indication	Hairy cell leukemia
TxGNN Prediction Score	0.9916
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for this drug in the compiled data. Based on known information, interferon beta-1b is a type I interferon. Its efficacy in relapsing-remitting MS is established, and it acts as an immune modulator.

The link to hairy cell leukemia comes from the interferon class. Interferon alpha was historically used to treat this leukemia. Interferon beta-1b signals through the same IFNAR receptor pathway, so antiproliferative and immunomodulatory effects are plausible.

This reasoning is at class level only, with no direct evidence for interferon beta-1b in this disease. Hairy cell leukemia treatment is now dominated by purine analogs (cladribine, pentostatin) and BRAF inhibitors, so there is little clinical need to pursue interferon beta-1b here.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02169649	BETASERON	Not specified	Not specified in the compiled data

Safety Considerations

Drug Interactions: The interaction screen returned 100 interacting drugs, of which the first 20 were reviewed.
- Major: Bupropion.
- Moderate, examples: acarbose, pioglitazone, rosiglitazone, clarithromycin, levofloxacin, minocycline, naltrexone, orlistat, rosuvastatin, simvastatin, oxandrolone, oxymetholone, stanozolol, chenodeoxycholic acid, nicotinamide, clotrimazole, and bowel-preparation agents (picosulfuric acid, polyethylene glycol with electrolytes, sodium sulfate).

For warnings and contraindications, please refer to the package insert.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score is very high (0.9916), but there are no clinical trials or publications for hairy cell leukemia, so the evidence level is L5. Current standard therapies are highly effective, which leaves little clinical need for this indication.

For context, the model’s second-ranked prediction, autoimmune disease of the central nervous system, has substantial supporting evidence. This includes a completed Phase 3 BENEFIT extension study (NCT00185211, 468 patients) and a Cochrane network meta-analysis. However, that evidence is essentially for MS, the drug’s already approved use, so it is not a true repurposing opportunity.

To proceed, the following is needed:

Direct preclinical or clinical evidence for interferon beta-1b in hairy cell leukemia
A comparison against current standard therapies (purine analogs, BRAF inhibitors) to establish unmet need
Mechanism of action data
Warnings and contraindications from the Health Canada package insert, for safety screening
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.